SUMMARY Suppression of platelet function is thought to be a mechanism of propranolol's beneficial action in angina pectoris. To study the effects of propranolol on platelets, we measured plasma ,8 thromboglobulin and plasma thromboxane B2 (TXB2, stable metabolite of TXA2) levels by radioimmunoassay as indexes of platelet a-granule and TXA2 release, respectively. Platelet TXA2 generation in vitro in response to arachidonate and thrombin was also quantitated. Twenty-nine patients with coronary disease 15 not taking propranolol (group A) and 14 taking propranolol (group B) and 15 normal subjects were studied. Plasma 1-thromboglobulin levels were increased in group A and B patients (mean 63 ± 8 and 96 + 14 ng/ ml, respectively) compared with normal subjects (mean 46 ± 6 ng/ml THERAPY with /3-adrenergic blocking agents such as propranolol has become a cornerstone in the management of patients with coronary artery disease. The major mechanism of action of these agents is believed to be reduction in myocardial oxygen demand both at rest and during exercise. Experimental and clinical evidence suggests that platelets and prostaglandins may be involved in the manifestations of coronary artery disease, such as angina pectoris and myocardial infarction.1'-Platelet activation may impede blood flow by intravascular aggregate formation.6 Release of thromboxane A, (TXA2) by platelets upon activation may be involved in compromising blood flow by its very potent vasoconstrictor action and pro-platelet aggregatory actions.7 8 Some recent studies indeed show platelet activation and elevated plasma TXA, concentrations in some patients with spontaneous angina9-1' and during pacing-induced myocardial ischemia.'2 Propranolol has been shown to have antiplatelet effects.'3 '9 In vitro, propranolol inhibits platelet aggregation, possibly by interfering with intracellular calcium mobilization.'5 A decrease in platelet aggregation at rest and during exercise has been proposed as one mechanism of the beneficial action of propranolol in reducing exercise-induced angina pectoris. 7 Because intracellular calcium mobilization is important in activation of enzyme phospholipase and subsequent synthesis of platelet TXA, synthesis, propranolol therapy might modify platelet TXA, generation in patients with coronary artery disease. 
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The purpose of this study was to examine platelet release reaction as an index of platelet activation and platelet TXA, generation in patients with coronary heart disease and in normal subjects.
Materials and Methods

Study Population
Twenty-nine patients with history of stable angina pectoris and 15 normal subjects with no clinical evidence of coronary heart disease were included in this study. Of the 29 patients with angina pectoris, 23 had coronary artery disease (> 50% luminal narrowing) documented by angiography. Four had one-vessel disease, 10 two-vessel disease, and nine three-vessel disease. Eleven patients had had a myocardial infarction. Six patients who did not undergo coronary angiography were believed to have coronary heart disease because of previous myocardial infarction, angina pectoris and ECG evidence of myocardial ischemia with exercise.
Fifteen of the 29 patients were not taking propranolol (group A). Fourteen patients had been taking propranolol for periods of 1-5 months (group B). The total daily dose of propranolol was 120-1320 mg (mean 231 + 22 mg). There were no significant differences in the extent of coronary artery disease between group A and group B patients. None of the study subjects had taken aspirin or other platelet-active drugs in the preceding week. All short-and long-acting nitrates were withheld from coronary heart disease patients for 6 hours, as these agents may interfere with platelet studies.2' Blood samples were collected in all subjects in the morning before eating and after 15 minutes of rest.
Blood Collection
All blood samples were collected from untraumatized peripheral veins. Blood was collected without tourniquet pressure, and only if blood flowed freely.
PLATELETS, PROSTAGLANDINS AND PROPRANOLOLIMehta and Mehta
The first 4 ml of blood were discarded. The subsequent 2.5 ml of blood were collected in a mixture of EDTA and theophylline (2.5:0.5, vol/vol) for /3-thromboglobulin assay, and the tube was immediately placed at 0°C after gentle shaking. Another 4 ml of blood was collected in a tube containing 1 mM of aspirin and 4.5 mM of EDTA (4:1, vol/vol) for TXB2 assay. The last blood sample (4.5 ml) was collected in sodium citrate (0.5 ml) for study of in vitro platelet TXA2 generation.
Beta-thromboglobulin determination was done using radioimmunoassay.22 24 The blood sample was centrifuged at 4°C for 30 minutes within 1 hour after collection. After centrifugation, the top 0. 5 generation has been described. 26 The platelet count in quots of PRP, arachidonic acid (33 ,ug/ml) or thrombin (10 IU/ml) were added. The PRP samples were incubated at 37°C for 5 minutes and then stored in solution containing aspirin and EDTA (4:1, vol/vol). TXB2 was measured in the samples as described above. All samples were assayed in duplicate, and the average expressed in pg/108 platelets was used for calculations.
Statistical Calculations
The average of all duplicate values was used to calculate the mean + SEM. The t test for unpaired data, the rank-sum test and linear regression analysis were used for statistical calculations. A value less than 0.05 was considered significant.
Results
Study Population
The mean age of coronary heart disease patients was similar in groups A and B (mean 60 + 2 and 57 + 3 years, respectively; NS). The normal subjects were somewhat younger (mean age 45 + 3 years).
Groups A and B were similar in terms of duration of symptoms (11 + 3 and 12 ± 2 months, respectively) and nitrate therapy. Angina was more frequent in group A patients than in group B patients (mean 4.4 + 1.1 and 2.5 + 0.5 episodes of chest pain per week, p < 0.01). However, none of the patients had a myocardial infarction in the preceding 2 months or an episode of chest pain within 12 hours of blood collection; therefore, an acute event did not account for platelet function abnormality.
Plasma B-thromboglobulin Concentrations
Duplicate determinations of plasma ,B-thromboglobulin concentrations showed a mean variation of 5%. Plasma 13-thromboglobulin levels in the normal subjects were 21-97 ng/ml (mean 46 + 6 ng/ml). In patients with coronary heart disease (n = 22), plasma ,8-thromboglobulin levels were significantly higher (mean 80 + 8 ng/ml, p < 0.001). The increased concentrations were observed in group A patients (range 30-123 ng/ml, mean 63 + 8 ng/ml) as well as in group B patients (range ng/ml, mean 96 + 14 ng/ml) ( fig. 1 ). However, there was no significant difference in plasma,3-thromboglobulin concentrations in group A and group B patients (63 + 8 and 96 ± 14 ng/ml, respectively; NS).
Plasma TXB2 Concentrations
Duplicate determinations of TXB2 concentrations in plasma samples showed a mean variation of 8%. In the normal subjects, TXB2 levels in the peripheral venous blood ranged from undetectable to 450 pg/ml (mean 216 + 39 pg/ml). These levels are in the same range as described by others.9-12 The plasma concentrations of TXB2 in patients with coronary heart disease (mean 148 + 27 pg/ml, n = 29) were not significantly different from those in normal subjects. In group A, plasma TXB2 levels ranged from undetectable to 700 pg/ml (mean 148 ± 41 pg/ml). Plasma TXB2 levels in group B patients ranged from undetectable to 440 pg/ml (mean 149 ± 36 pg/ml) and were similar to those in 1295 UD'ir-NIP was adjusted to 300,000 400,000/mm'. To ali- group A patients and normal subjects ( fig. 2 ). There was no significant correlation between plasma ,3-thromboglobulin and TXB2 concentrations in either the normal subjects (r = 0.22) or coronary heart disease patients (r = 0.35).
Platelet TXA2 Generation
Normal subjects and coronary heart disease patients showed important differences in in vitro TXA2 generation by platelets. The mean arachidonate-induced platelet TXA2 generation in normal subjects was 82 + 25 pg TXB2/108 platelets (range 0-350 pg/ml). In group A, TXA, generation was more than 2 [22] [23] [24] 27 and platelet survival in vivo. 28 Patients with angina pectoris and myocardial infarction have a marked increase in /3 thromboglobulin as well as in platelet factor 4, another protein released from a granules.29 A close correlation between these two platelet-release products has been observed.30 Measurement of these release products is a better index of platelet activity than in vitro tests such as platelet aggregation. The present study again confirms elevations in plasma,l/-thromboglobulin concentrations in some patients with coronary heart disease.
In vivo platelet activation would also be expected to cause release of TXA2, a very potent vasoconstrictor and platelet aggregant. However, the very short halflife of TXA2 precludes its direct measurement. Its stable metabolite, TXB2, can be measured by several techniques.9 12 In most patients with stable coronary heart disease, resting plasma TXB2 levels have been reported to be normal. Nevertheless, spontaneous or acute exacerbation of coronary heart disease may result in marked elevations in plasma concentration of TXB2 in some patients."" No direct correlation between resting plasma thromboglobulin and TXB2 concentrations exists, as seen in this and other reports.'0' 27 This lack of correlation probably relates to different half-lives of the two platelet-derived products.
Propranolol has been reported to inhibit platelet aggregation and adhesion and serotonin uptake and release in vitro. 1116 In most patients taking propranolol, a marked reduction in platelet aggregation compared with patients not taking propranolol has been observed. 1'-19 These effects of propranolol are thought to be related to its generalized local-anesthetic-like, membrane-stabilizing activity on the platelets. Since addition of ionophore A23 187 in the medium counters reduction in platelet aggregation by propranolol, its platelet inhibitory effects are probably due to interference with calcium mobilization in the platelets. Al 33 34 These mechanisms may be involved not only in the genesis of clinical manifestations of coronary heart disease, but also in the evolution and propagation of atherosclerosis.4 5 Inhibition of platelet TXA2 generation by propranolol may be important in modifying the abnormal platelet-vessel wall interaction in patients with coronary heart disease.
In conclusion, routine propranolol therapy markedly reduces the capability of platelets to generate TXA2. This finding could be related to modification of hemodynamic effects of stress by propranolol in patients with coronary heart disease. However, variables of platelet activation such as plasma ,3 thromboglobulin at rest are not modified by routine propranolol therapy.
vivo, and part of its beneficial effect may result from this inhibition.
We recently demonstrated that nitroglycerin induces human endothelial cells in tissue culture to synthesize prostacyclin (PG12),7 a potent, naturally occurring vasodilator and platelet inhibitor.9' 10 The PG12 produced by these endothelial cells inhibits platelet aggregation in vitro. To explore the hypothesis that NP modulates vascular tone and relieves ischemia by shifting the ratio of PGI, to thromboxane A2 (TXA2) in the circulation toward PG12 excess, we studied the effect of NP on endothelial cells and platelets.
Methods Platelet Aggregation and Thromboxane B2 Production Platelet-rich plasma (PRP) was prepared from venous blood and platelet counts were determined on a model ZBI Coulter counter by methods described. " Aggregation was induced with the following aggregating agents (expressed as final concentration in the cuvette): sodium arachidonate (Nu Chek), 0.1-3 mM; fibrillar bovine collagen (Hormon-Chemie), 0.6-1.6 jig/ml; and epinephrine (Parke Davis), 2-4.3 ,uM.
Platelet aggregation was performed in a dual-channel
